Direct and indirect effects of psychopharmacological treatment on the cardiovascular system

References

[1] Babigian HM, Odoroff CL. The mortality experience of a population with psychiatric illness. Am J Psychiatry. 1969;126:470–80.10.1176/ajp.126.4.470Suche in Google Scholar PubMed

[2] Harris EC, Barraclough B. Excess mortality of mental disorder. Br J Psychiatry. 1998;173:11–53.10.1192/bjp.173.1.11Suche in Google Scholar PubMed

[3] Ivbijaro G. Excess mortality in severe mental disorder: the need for an integrated approach. World Psychiatry. 2017;16:48–9.10.1002/wps.20382Suche in Google Scholar PubMed PubMed Central

[4] Lawrence D. Excess mortality, mental illness and global burden of disease. Epidemiol Psychiatr Sci. 2015;24:141–3.10.1017/S2045796014000742Suche in Google Scholar PubMed PubMed Central

[5] Liu NH, Daumit GL, Dua T, Aquila R, Charlson F, Cuijpers P, et al. Excess mortality in persons with severe mental disorders: a multilevel intervention framework and priorities for clinical practice, policy and research agendas. World Psychiatry. 2017;16:30–40.10.1002/wps.20384Suche in Google Scholar PubMed PubMed Central

[6] Lumme S, Pirkola S, Manderbacka K, Keskimaki I. Excess mortality in patients with severe mental disorders in 1996–2010 in Finland. PLoS One. 2016;11:e0152223.10.1371/journal.pone.0152223Suche in Google Scholar PubMed PubMed Central

[7] Miller C, Bauer MS. Excess mortality in bipolar disorders. Curr Psychiatry Rep. 2014;16:499.10.1007/s11920-014-0499-zSuche in Google Scholar PubMed

[8] Nordentoft M, Wahlbeck K, Hallgren J, Westman J, Osby U, Alinaghizadeh H, et al. Excess mortality, causes of death and life expectancy in 270,770 patients with recent onset of mental disorders in Denmark, Finland and Sweden. PLoS One. 2013;8:e55176.10.1371/journal.pone.0055176Suche in Google Scholar PubMed PubMed Central

[9] Pratt LA, Druss BG, Manderscheid RW, Walker ER. Excess mortality due to depression and anxiety in the United States: results from a nationally representative survey. Gen Hosp Psychiatry. 2016;39:39–45.10.1016/j.genhosppsych.2015.12.003Suche in Google Scholar PubMed PubMed Central

[10] Saha S, Chant D, McGrath J. A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time? Arch Gen Psychiatry. 2007;64:1123–31.10.1001/archpsyc.64.10.1123Suche in Google Scholar PubMed

[11] Tidemalm D, Waern M, Stefansson CG, Elofsson S, Runeson B. Excess mortality in persons with severe mental disorder in Sweden: a cohort study of 12 103 individuals with and without contact with psychiatric services. Clin Pract Epidemiol Ment Health. 2008;4:23.10.1186/1745-0179-4-23Suche in Google Scholar

[12] Walker ER, McGee RE, Druss BG. Mortality in mental disorders and global disease burden implications: a systematic review and meta-analysis. JAMA Psychiatry. 2015;72:334–41.10.1001/jamapsychiatry.2014.2502Suche in Google Scholar PubMed PubMed Central

[13] Malzberg B. Life tables for patients with mental disease. J Am Stat Assoc. 1932;27:160–74.10.2307/2277862Suche in Google Scholar

[14] Chesney E, Goodwin GM, Fazel S. Risks of all-cause and suicide mortality in mental disorders: a meta-review. World Psychiatry. 2014;13:153–60.10.1002/wps.20128Suche in Google Scholar PubMed PubMed Central

[15] Fekadu A, Medhin G, Kebede D, Alem A, Cleare AJ, Prince M, et al. Excess mortality in severe mental illness: 10-year population-based cohort study in rural Ethiopia. Br J Psychiatry. 2015;206:289–96.10.1192/bjp.bp.114.149112Suche in Google Scholar PubMed

[16] Ho C, Jin A, Nyunt MS, Feng L, Ng TP. Mortality rates in major and subthreshold depression: 10-year follow-up of a Singaporean population cohort of older adults. Postgrad Med. 2016;128:642–7.10.1080/00325481.2016.1221319Suche in Google Scholar PubMed

[17] Laursen TM, Nordentoft M, Mortensen PB. Excess early mortality in schizophrenia. Annu Rev Clin Psychol. 2014;10:425–48.10.1146/annurev-clinpsy-032813-153657Suche in Google Scholar PubMed

[18] Olfson M, Gerhard T, Huang C, Crystal S, Stroup TS. Premature mortality among adults with schizophrenia in the United States. JAMA Psychiatry. 2015;72:1172–81.10.1001/jamapsychiatry.2015.1737Suche in Google Scholar PubMed

[19] Wahlbeck K, Westman J, Nordentoft M, Gissler M, Laursen TM. Outcomes of Nordic mental health systems: life expectancy of patients with mental disorders. Br J Psychiatry. 2011;199:453–8.10.1192/bjp.bp.110.085100Suche in Google Scholar PubMed

[20] Cuijpers P, Vogelzangs N, Twisk J, Kleiboer A, Li J, Penninx BW. Differential mortality rates in major and subthreshold depression: meta-analysis of studies that measured both. Br J Psychiatry. 2013;202:22–7.10.1192/bjp.bp.112.112169Suche in Google Scholar PubMed

[21] Newcomer JW, Hennekens CH. Severe mental illness and risk of cardiovascular disease. JAMA. 2007;298:1794–6.10.1001/jama.298.15.1794Suche in Google Scholar PubMed

[22] Brown S, Kim M, Mitchell C, Inskip H. Twenty-five year mortality of a community cohort with schizophrenia. Br J Psychiatry. 2010;196:116–21.10.1192/bjp.bp.109.067512Suche in Google Scholar

[23] Osby U, Westman J, Hallgren J, Gissler M. Mortality trends in cardiovascular causes in schizophrenia, bipolar and unipolar mood disorder in Sweden 1987–2010. Eur J Public Health. 2016;26:867–71.10.1093/eurpub/ckv245Suche in Google Scholar

[24] Vigo D, Thornicroft G, Atun R. Estimating the true global burden of mental illness. Lancet Psychiatry. 3:171–8.10.1016/S2215-0366(15)00505-2Suche in Google Scholar

[25] Colton CW, Manderscheid RW. Congruencies in increased mortality rates, years of potential life lost, and causes of death among public mental health clients in eight states. Prev Chronic Dis. 2006;3:A42.Suche in Google Scholar

[26] Kritharides L, Chow V, Lambert TJ. Cardiovascular disease in patients with schizophrenia. Med J Aust. 2017;206:91–5.10.5694/mja16.00650Suche in Google Scholar PubMed

[27] Lawrence D, Hancock KJ, Kisely S. The gap in life expectancy from preventable physical illness in psychiatric patients in Western Australia: retrospective analysis of population based registers. BMJ. 2013;346:f2539.10.1136/bmj.f2539Suche in Google Scholar PubMed PubMed Central

[28] Laursen TM, Munk-Olsen T, Nordentoft M, Mortensen PB. Increased mortality among patients admitted with major psychiatric disorders: a register-based study comparing mortality in unipolar depressive disorder, bipolar affective disorder, schizoaffective disorder, and schizophrenia. J Clin Psychiatry. 2007;68:899–907.10.4088/JCP.v68n0612Suche in Google Scholar

[29] Roshanaei-Moghaddam B, Katon W. Premature mortality from general medical illnesses among persons with bipolar disorder: a review. Psychiatr Serv. 2009;60:147–56.10.1176/ps.2009.60.2.147Suche in Google Scholar PubMed

[30] Lambert TJ, Velakoulis D, Pantelis C. Medical comorbidity in schizophrenia. Med J Aust. 2003;178 (Suppl):S67–70.10.5694/j.1326-5377.2003.tb05311.xSuche in Google Scholar PubMed

[31] Davidson S, Judd F, Jolley D, Hocking B, Thompson S, Hyland B. Cardiovascular risk factors for people with mental illness. Aust N Z J Psychiatry. 2001;35:196–202.10.1046/j.1440-1614.2001.00877.xSuche in Google Scholar PubMed

[32] McCreadie RG, Scottish Schizophrenia Lifestyle Group. Diet, smoking and cardiovascular risk in people with schizophrenia: descriptive study. Br J Psychiatry. 2003;183:534–9.10.1192/03-162Suche in Google Scholar

[33] Lang UE, Borgwardt S. Molecular mechanisms of depression: perspectives on new treatment strategies. Cell Physiol Biochem. 2013;31:761–77.10.1159/000350094Suche in Google Scholar

[34] Chaddha A, Robinson EA, Kline-Rogers E, Alexandris-Souphis T, Rubenfire M. Mental health and cardiovascular disease. Am J Med. 2016;129:1145–8.10.1016/j.amjmed.2016.05.018Suche in Google Scholar

[35] Lichtman JH, Froelicher ES, Blumenthal JA, Carney RM, Doering LV, Frasure-Smith N, et al. Depression as a risk factor for poor prognosis among patients with acute coronary syndrome: systematic review and recommendations: a scientific statement from the American Heart Association. Circulation. 2014;129:1350–69.10.1161/CIR.0000000000000019Suche in Google Scholar

[36] Stringhini S, Carmeli C, Jokela M, Avendaño M, Muennig P, Guida F, et al. Socioeconomic status and the 25 × 25 risk factors as determinants of premature mortality: a multicohort study and meta-analysis of 1.7 million men and women. The Lancet. 2017;389:1194.10.1016/S0140-6736(16)32380-7Suche in Google Scholar

[37] Andreassen OA, Djurovic S, Thompson WK, Schork AJ, Kendler KS, O’Donovan MC, et al. Improved detection of common variants associated with schizophrenia by leveraging pleiotropy with cardiovascular-disease risk factors. Am J Hum Genet. 2013;92:197–209.10.1016/j.ajhg.2013.01.001Suche in Google Scholar PubMed PubMed Central

[38] Laursen TM, Nordentoft M. Heart disease treatment and mortality in schizophrenia and bipolar disorder – changes in the Danish population between 1994 and 2006. J Psychiatr Res. 2011;45:29–35.10.1016/j.jpsychires.2010.04.027Suche in Google Scholar PubMed

[39] Lawrence D, Kisely S. Inequalities in healthcare provision for people with severe mental illness. J Psychopharmacol. 2010;24(4 Suppl):61–8.10.1177/1359786810382058Suche in Google Scholar PubMed PubMed Central

[40] Cunningham C, Peters K, Mannix J. Physical health inequities in people with severe mental illness: identifying initiatives for practice change. Issues Ment Health Nurs. 2013;34:855–62.10.3109/01612840.2013.832826Suche in Google Scholar PubMed

[41] Albrecht J, Muller-Oerlinghausen B. [Cardiovascular side effects of lithium]. Dtsch Med Wochenschr. 1980;105:651–5.10.1007/978-94-011-7197-7_36Suche in Google Scholar

[42] Astrup T, Rasmussen J. Is there an enhancing effect of neuroleptic drugs on blood coagulation and thrombosis. Thromb Diath Haemorrh. 1965;13:418–27.10.1055/s-0038-1656241Suche in Google Scholar

[43] Axelsson S, Hagg S, Eriksson AC, Lindahl TL, Whiss PA. In vitro effects of antipsychotics on human platelet adhesion and aggregation and plasma coagulation. Clin Exp Pharmacol Physiol. 2007;34:775–80.10.1111/j.1440-1681.2007.04650.xSuche in Google Scholar

[44] Blankfield RP. Blood pressure, fluid retention and the cardiovascular risk of drugs. Future Cardiol. 2012;8:489–93.10.2217/fca.12.39Suche in Google Scholar

[45] Akoudad S, Aarts N, Noordam R, Ikram MA, Tiemeier H, Hofman A, et al. Antidepressant use is associated with an increased risk of developing microbleeds. Stroke. 2016;47:251–4.10.1161/STROKEAHA.115.011574Suche in Google Scholar

[46] Auguet M, Clostre F, DeFeudis FV. Effects of antidepressants on receptor-activated and Ca2+-activated contractions of rabbit isolated aorta. Gen Pharmacol. 1986;17:607–10.10.1016/0306-3623(86)90103-5Suche in Google Scholar

[47] Gothe F, Enache D, Wahlund LO, Winblad B, Crisby M, Lokk J, et al. Cerebrovascular diseases and depression: epidemiology, mechanisms and treatment. Panminerva Med. 2012;54:161–70.Suche in Google Scholar

[48] Grool AM, van der Graaf Y, Vincken KL, Witkamp TD, Mali WP, Geerlings MI. Antidepressant use is related to larger white matter lesion volume in patients with symptomatic atherosclerotic disease: the SMART-MR study. J Neurol. 2013;260:197–206.10.1007/s00415-012-6616-1Suche in Google Scholar PubMed

[49] Correll CU, Detraux J, De Lepeleire J, De Hert M. Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder. World Psychiatry. 2015;14:119–36.10.1002/wps.20204Suche in Google Scholar PubMed PubMed Central

[50] Bachmann CJ, Aagaard L, Burcu M, Glaeske G, Kalverdijk LJ, Petersen I, et al. Trends and patterns of antidepressant use in children and adolescents from five western countries, 2005–2012. Eur Neuropsychopharmacol. 2016;26:411–19.10.1016/j.euroneuro.2016.02.001Suche in Google Scholar PubMed

[51] Pratt LA, Brody DJ, Gu Q. Antidepressant use in persons aged 12 and over: United States, 2005–2008. NCHS Data Brief. 2011:1–8.Suche in Google Scholar

[52] Mars B, Heron J, Kessler D, Davies NM, Martin RM, Thomas KH, et al. Influences on antidepressant prescribing trends in the UK: 1995–2011. Soc Psychiatry Psychiatr Epidemiol. 2017;52:193–200.10.1007/s00127-016-1306-4Suche in Google Scholar PubMed PubMed Central

[53] Lippi G, Montagnana M, Favaloro EJ, Franchini M. Mental depression and cardiovascular disease: a multifaceted, bidirectional association. Semin Thromb Hemost. 2009;35:325–36.10.1055/s-0029-1222611Suche in Google Scholar PubMed

[54] Bushnell C. Depression and the risk of stroke in women: an identification and treatment paradox. Stroke. 2011;42:2718–9.10.1161/STROKEAHA.111.626895Suche in Google Scholar PubMed

[55] Clarke DM, Currie KC. Depression, anxiety and their relationship with chronic diseases: a review of the epidemiology, risk and treatment evidence. Med J Aust. 2009;190(7 Suppl):S54–60.10.5694/j.1326-5377.2009.tb02471.xSuche in Google Scholar PubMed

[56] Davidson KW, Korin MR. Depression and cardiovascular disease: selected findings, controversies, and clinical implications from 2009. Cleve Clin J Med. 2010;77(Suppl 3):S20–6.10.3949/ccjm.77.s3.04Suche in Google Scholar PubMed PubMed Central

[57] Ghoge H, Sharma S, Sonawalla S, Parikh R. Cerebrovascular diseases and depression. Curr Psychiatry Rep. 2003;5:231–8.10.1007/s11920-003-0048-7Suche in Google Scholar PubMed

[58] Hare DL, Toukhsati SR, Johansson P, Jaarsma T. Depression and cardiovascular disease: a clinical review. Eur Heart J. 2014;35:1365–72.10.1093/eurheartj/eht462Suche in Google Scholar PubMed

[59] Li CT, Bai YM, Tu PC, Lee YC, Huang YL, Chen TJ, et al. Major depressive disorder and stroke risks: a 9-year follow-up population-based, matched cohort study. PLoS One. 2012;7:e46818.10.1371/journal.pone.0046818Suche in Google Scholar PubMed PubMed Central

[60] Moretti R, Bernobich E, Esposito F, Torre P, Antonello RM, De Angelis L, et al. Depression in vascular pathologies: the neurologist’s point of view. Vasc Health Risk Manag. 2011;7:433–43.10.2147/VHRM.S20147Suche in Google Scholar PubMed PubMed Central

[61] Coupland C, Hill T, Morriss R, Moore M, Arthur A, Hippisley-Cox J. Antidepressant use and risk of cardiovascular outcomes in people aged 20 to 64: cohort study using primary care database. BMJ. 2016;352:i1350.10.1136/bmj.i1350Suche in Google Scholar PubMed PubMed Central

[62] Beach SR, Celano CM, Noseworthy PA, Januzzi JL, Huffman JC. QTc prolongation, torsades de pointes, and psychotropic medications. Psychosomatics. 2013;54:1–13.10.1016/j.psym.2012.11.001Suche in Google Scholar PubMed

[63] Beach SR, Kostis WJ, Celano CM, Januzzi JL, Ruskin JN, Noseworthy PA, et al. Meta-analysis of selective serotonin reuptake inhibitor-associated QTc prolongation. J Clin Psychiatry. 2014;75:e441–9.10.4088/JCP.13r08672Suche in Google Scholar PubMed

[64] Bouffard Y, Palmier B, Bouletreau P, Motin J. [Acute tricyclic antidepressant intoxication. Evaluation of severity and treatment. A study of 16 patients with cardiovascular manifestations (author’s transl)]. Ann Med Interne (Paris). 1982;133:256–60.Suche in Google Scholar

[65] Funai Y, Funao T, Ikenaga K, Takahashi R, Hase I, Nishikawa K. Use of tricyclic antidepressants as analgesic adjuvants results in nonhazardous prolongation of the QTc interval. Osaka City Med J. 2014;60:11–9.Suche in Google Scholar

[66] Golacka E. [Intoxication with tricyclic antidepressants in 2000: regional toxicological poison data from the center in Lublin]. Przegl Lek. 2003;60:289–91.Suche in Google Scholar

[67] Hasnain M, Vieweg WV. QTc interval prolongation and torsade de pointes associated with second-generation antipsychotics and antidepressants: a comprehensive review. CNS Drugs. 2014;28:887–920.10.1007/s40263-014-0196-9Suche in Google Scholar PubMed

[68] Jasiak NM, Bostwick JR. Risk of QT/QTc prolongation among newer non-SSRI antidepressants. Ann Pharmacother. 2014;48:1620–8.10.1177/1060028014550645Suche in Google Scholar PubMed

[69] Maljuric NM, Noordam R, Aarts N, Niemeijer MN, van den Berg ME, Hofman A, et al. Use of selective serotonin re-uptake inhibitors and the heart rate corrected QT interval in a real-life setting: the population-based Rotterdam Study. Br J Clin Pharmacol. 2015;80:698–705.10.1111/bcp.12681Suche in Google Scholar PubMed PubMed Central

[70] Mitsumori Y, Nakamura Y, Hoshiai K, Nagayama Y, Adachi-Akahane S, Koizumi S, et al. In vivo canine model comparison of cardiovascular effects of antidepressants milnacipran and imipramine. Cardiovasc Toxicol. 2010;10:275–82.10.1007/s12012-010-9084-9Suche in Google Scholar PubMed

[71] Pacher P, Kecskemeti V. Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns? Curr Pharm Des. 2004;10:2463–75.10.2174/1381612043383872Suche in Google Scholar PubMed PubMed Central

[72] Sala M, Coppa F, Cappucciati C, Brambilla P, d’Allio G, Caverzasi E, et al. Antidepressants: their effects on cardiac channels, QT prolongation and Torsade de Pointes. Curr Opin Investig Drugs. 2006;7:256–63.Suche in Google Scholar

[73] Spindelegger CJ, Papageorgiou K, Grohmann R, Engel R, Greil W, Konstantinidis A, et al. Cardiovascular adverse reactions during antidepressant treatment: a drug surveillance report of German-speaking countries between 1993 and 2010. Int J Neuropsychopharmacol. 2014;18. DOI: 10.1093/ijnp/pyu080.10.1093/ijnp/pyu080Suche in Google Scholar PubMed PubMed Central

[74] Thanacoody HK, Thomas SH. Tricyclic antidepressant poisoning: cardiovascular toxicity. Toxicol Rev. 2005;24:205–14.10.2165/00139709-200524030-00013Suche in Google Scholar PubMed

[75] Tisdale JE. Drug-induced QT interval prolongation and torsades de pointes: role of the pharmacist in risk assessment, prevention and management. Can Pharm J (Ott). 2016;149:139–52.10.1177/1715163516641136Suche in Google Scholar PubMed PubMed Central

[76] Uchida M, Spencer AE, Biederman J, Castro VM, Kenworthy T, Chan J, et al. A systematic evaluation of the QTc interval and antidepressants in youth: an electronic health record study. J Dev Behav Pediatr. 2015;36:434–9.10.1097/DBP.0000000000000188Suche in Google Scholar PubMed

[77] Wenzel-Seifert K, Wittmann M, Haen E. QTc prolongation by psychotropic drugs and the risk of Torsade de Pointes. Dtsch Arztebl Int. 2011;108:687–93.10.3238/arztebl.2011.0687Suche in Google Scholar PubMed PubMed Central

[78] Delini-Stula A, Baier D, Kohnen R, Laux G, Philipp M, Scholz HJ. Undesirable blood pressure changes under naturalistic treatment with moclobemide, a reversible MAO-A inhibitor – results of the drug utilization observation studies. Pharmacopsychiatry. 1999;32:61–7.10.1055/s-2007-979193Suche in Google Scholar PubMed

[79] Georgotas A, McCue RE, Friedman E, Cooper TB. A placebo-controlled comparison of the effect of nortriptyline and phenelzine on orthostatic hypotension in elderly depressed patients. J Clin Psychopharmacol. 1987;7:413–6.10.1097/00004714-198712000-00008Suche in Google Scholar

[80] Johnson EM, Whyte E, Mulsant BH, Pollock BG, Weber E, Begley AE, et al. Cardiovascular changes associated with venlafaxine in the treatment of late-life depression. Am J Geriatr Psychiatry. 2006;14:796–802.10.1097/01.JGP.0000204328.50105.b3Suche in Google Scholar PubMed

[81] Kiev A, Masco HL, Wenger TL, Johnston JA, Batey SR, Holloman LC. The cardiovascular effects of bupropion and nortriptyline in depressed outpatients. Ann Clin Psychiatry. 1994;6:107–15.10.3109/10401239409148989Suche in Google Scholar PubMed

[82] Laird LK, Lydiard RB, Morton WA, Steele TE, Kellner C, Thompson NM, et al. Cardiovascular effects of imipramine, fluvoxamine, and placebo in depressed outpatients. J Clin Psychiatry. 1993;54:224–8.Suche in Google Scholar

[83] Leinonen E, Lepola U, Koponen H, Mehtonen OP, Rimon R. Long-term efficacy and safety of milnacipran compared to clomipramine in patients with major depression. Acta Psychiatr Scand. 1997;96:497–504.10.1111/j.1600-0447.1997.tb09953.xSuche in Google Scholar PubMed

[84] Neshkes RE, Gerner R, Jarvik LF, Mintz J, Joseph J, Linde S, et al. Orthostatic effect of imipramine and doxepin in depressed geriatric outpatients. J Clin Psychopharmacol. 1985;5:102–6.10.1097/00004714-198504000-00009Suche in Google Scholar PubMed

[85] Ottevanger EA. Fluvoxamine and clomipramine in depressed hospitalised patients: results from a randomised, double-blind study. Encephale. 1995;21:317–21.Suche in Google Scholar

[86] Roberts RL, Joyce PR, Mulder RT, Begg EJ, Kennedy MA. A common P-glycoprotein polymorphism is associated with nortriptyline-induced postural hypotension in patients treated for major depression. Pharmacogenomics J. 2002;2:191–6.10.1038/sj.tpj.6500099Suche in Google Scholar PubMed

[87] Tricyclic antidepressants. N Engl J Med. 1979;300:504–6.10.1056/NEJM197903013000923Suche in Google Scholar PubMed

[88] Hoc J. The clinical efficacy and side-effects of mianserin and nortriptyline in depressed out-patients: a double-blind randomized trial. Curr Med Res Opin. 1982;8:282–9.10.1185/03007998209109779Suche in Google Scholar PubMed

[89] Schneider LS, Cooper TB, Severson JA, Zemplenyi T, Sloane RB. Electrocardiographic changes with nortriptyline and 10-hydroxynortriptyline in elderly depressed outpatients. J Clin Psychopharmacol. 1988;8:402–8.10.1097/00004714-198812000-00004Suche in Google Scholar

[90] Veith RC, Raskind MA, Caldwell JH, Barnes RF, Gumbrecht G, Ritchie JL. Cardiovascular effects of tricyclic antidepressants in depressed patients with chronic heart disease. N Engl J Med. 1982;306:954–9.10.1056/NEJM198204223061603Suche in Google Scholar PubMed

[91] Castro VM, Clements CC, Murphy SN, Gainer VS, Fava M, Weilburg JB, et al. QT interval and antidepressant use: a cross sectional study of electronic health records. BMJ. 2013;346:f288.10.1136/bmj.f288Suche in Google Scholar PubMed PubMed Central

[92] Coupland CA, Dhiman P, Barton G, Morriss R, Arthur A, Sach T, et al. A study of the safety and harms of antidepressant drugs for older people: a cohort study using a large primary care database. Health Technol Assess. 2011;15:1–202, iii–iv.10.3310/hta15280Suche in Google Scholar PubMed

[93] Glassman AH. Cardiovascular effects of antidepressant drugs: updated. Int Clin Psychopharmacol. 1998;13(Suppl 5):S25–30.10.1097/00004850-199809005-00006Suche in Google Scholar PubMed

[94] Andrade C, Sandarsh S, Chethan KB, Nagesh KS. Serotonin reuptake inhibitor antidepressants and abnormal bleeding: a review for clinicians and a reconsideration of mechanisms. J Clin Psychiatry. 2010;71:1565–75.10.4088/JCP.09r05786bluSuche in Google Scholar PubMed

[95] Cheng YL, Hu HY, Lin XH, Luo JC, Peng YL, Hou MC, et al. Use of SSRI, but not SNRI, increased upper and lower gastrointestinal bleeding: a nationwide population-based cohort study in Taiwan. Medicine (Baltimore). 2015;94:e2022.10.1097/MD.0000000000002022Suche in Google Scholar PubMed PubMed Central

[96] Coupland C, Dhiman P, Morriss R, Arthur A, Barton G, Hippisley-Cox J. Antidepressant use and risk of adverse outcomes in older people: population based cohort study. BMJ. 2011;343:d4551.10.1136/bmj.d4551Suche in Google Scholar PubMed PubMed Central

[97] Quinn GR, Singer DE, Chang Y, Go AS, Borowsky LH, Udaltsova N, et al. Effect of selective serotonin reuptake inhibitors on bleeding risk in patients with atrial fibrillation taking warfarin. Am J Cardiol. 2014;114:583–6.10.1016/j.amjcard.2014.05.037Suche in Google Scholar PubMed PubMed Central

[98] Morriss R. Antidepressants are associated with hospital admitted intracranial bleeds in people taking other medication associated with bleeding. Evid Based Ment Health. 2016;19:24.10.1136/eb-2015-102212Suche in Google Scholar PubMed

[99] Shin JY, Park MJ, Lee SH, Choi SH, Kim MH, Choi NK, et al. Risk of intracranial haemorrhage in antidepressant users with concurrent use of non-steroidal anti-inflammatory drugs: nationwide propensity score matched study. BMJ. 2015;351:h3517.10.1136/bmj.h3517Suche in Google Scholar PubMed PubMed Central

[100] Salvi V, Mencacci C, Barone-Adesi F. H1-histamine receptor affinity predicts weight gain with antidepressants. Eur Neuropsychopharmacol. 2016;26:1673–7.10.1016/j.euroneuro.2016.08.012Suche in Google Scholar PubMed

[101] Andersohn F, Schade R, Suissa S, Garbe E. Long-term use of antidepressants for depressive disorders and the risk of diabetes mellitus. Am J Psychiatry. 2009;166:591–8.10.1176/appi.ajp.2008.08071065Suche in Google Scholar PubMed

[102] Pan A, Sun Q, Okereke OI, Rexrode KM, Rubin RR, Lucas M, et al. Use of antidepressant medication and risk of type 2 diabetes: results from three cohorts of US adults. Diabetologia. 2012;55:63–72.10.1007/s00125-011-2268-4Suche in Google Scholar PubMed PubMed Central

[103] Ratliff S, Mezuk B. Depressive symptoms, psychiatric medication use, and risk of type 2 diabetes: results from the Health and Retirement Study. Gen Hosp Psychiatry. 2015;37:420–6.10.1016/j.genhosppsych.2015.05.008Suche in Google Scholar PubMed PubMed Central

[104] Barnard K, Peveler RC, Holt RI. Antidepressant medication as a risk factor for type 2 diabetes and impaired glucose regulation: systematic review. Diabetes Care. 2013;36:3337–45.10.2337/dc13-0560Suche in Google Scholar PubMed PubMed Central

[105] Kammer JR, Hosler AS, Leckman-Westin E, DiRienzo G, Osborn CY. The association between antidepressant use and glycemic control in the Southern Community Cohort Study (SCCS). J Diabetes Complications. 2016;30:242–7.10.1016/j.jdiacomp.2015.10.017Suche in Google Scholar PubMed PubMed Central

[106] Da Silva MA, Dugravot A, Balkau B, Roussel R, Fumeron F, Elbaz A, et al. Antidepressant medication use and trajectories of fasting plasma glucose, glycated haemoglobin, beta-cell function and insulin sensitivity: a 9-year longitudinal study of the D.E.S.I.R. cohort. Int J Epidemiol. 2015;44:1927–40.10.1093/ije/dyv153Suche in Google Scholar PubMed

[107] Kivimaki M, Batty GD, Jokela M, Ebmeier KP, Vahtera J, Virtanen M, et al. Antidepressant medication use and risk of hyperglycemia and diabetes mellitus: a noncausal association? Biol Psychiatry. 2011;70:978–84.10.1016/j.biopsych.2011.07.008Suche in Google Scholar PubMed PubMed Central

[108] Funk KA, Bostwick JR. A comparison of the risk of QT prolongation among SSRIs. Ann Pharmacother. 2013;47:1330–41.10.1177/1060028013501994Suche in Google Scholar PubMed

[109] FDA. n.d. Drug Safety Communication: Revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses. MedWatch.Suche in Google Scholar

[110] FDA. n.d. Drug Safety Communication: Abnormal heart rhythms associated with high doses of Celexa (citalopram hydrobromide).Suche in Google Scholar

[111] Qirjazi E, McArthur E, Nash DM, Dixon SN, Weir MA, Vasudev A, et al. Risk of ventricular arrhythmia with citalopram and escitalopram: a population-based study. PLoS One. 2016;11:e0160768.10.1371/journal.pone.0160768Suche in Google Scholar PubMed PubMed Central

[112] Lam RW. Antidepressants and QTc prolongation. J Psychiatry Neurosci. 2013;38:E5–6.10.1503/jpn.120256Suche in Google Scholar PubMed PubMed Central

[113] Kahl KG, Westhoff-Bleck M, Kruger THC. Effects of psychopharmacological treatment with antidepressants on the vascular system. Vascul Pharmacol. 2017;96–98:11–8.10.1016/j.vph.2017.07.004Suche in Google Scholar PubMed

[114] Haritos VS, Ghabrial H, Ahokas JT, Ching MS. Role of cytochrome P450 2D6 (CYP2D6) in the stereospecific metabolism of E- and Z-doxepin. Pharmacogenetics. 2000;10:591–603.10.1097/00008571-200010000-00003Suche in Google Scholar PubMed

[115] Crone CC, Gabriel GM. Treatment of anxiety and depression in transplant patients: pharmacokinetic considerations. Clin Pharmacokinet. 2004;43:361–94.10.2165/00003088-200443060-00002Suche in Google Scholar PubMed

[116] Thase ME, Larsen KG, Reines E, Kennedy SH. The cardiovascular safety profile of escitalopram. Eur Neuropsychopharmacol. 2013;23:1391–400.10.1016/j.euroneuro.2013.05.011Suche in Google Scholar PubMed

[117] Carceller-Sindreu M, de Diego-Adelino J, Portella MJ, Garcia-Moll X, Figueras M, Fernandez-Vidal A, et al. Lack of relationship between plasma levels of escitalopram and QTc-interval length. Eur Arch Psychiatry Clin Neurosci. 2017;267:815–822.10.1007/s00406-016-0758-6Suche in Google Scholar PubMed

[118] Pacher P, Ungvari Z, Kecskemeti V, Koller A. Serotonin reuptake inhibitor, fluoxetine, dilates isolated skeletal muscle arterioles. Possible role of altered Ca2+ sensitivity. Br J Pharmacol. 1999;127:740–6.10.1038/sj.bjp.0702571Suche in Google Scholar PubMed PubMed Central

[119] Ungvari Z, Pacher P, Koller A. Serotonin reuptake inhibitor fluoxetine decreases arteriolar myogenic tone by reducing smooth muscle [Ca2+]i. J Cardiovasc Pharmacol. 2000;35:849–54.10.1097/00005344-200006000-00004Suche in Google Scholar PubMed

[120] Baumann P. Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors. Clin Pharmacokinet. 1996;31:444–69.10.2165/00003088-199631060-00004Suche in Google Scholar PubMed

[121] Kim J, Phongsamran P, Park S. Use of antidepressant drugs in transplant recipients. Prog Transplant. 2004;14:98–104.10.1177/152692480401400204Suche in Google Scholar

[122] Hicks JK, Swen JJ, Thorn CF, Sangkuhl K, Kharasch ED, Ellingrod VL, et al. Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants. Clin Pharmacol Ther. 2013;93:402–8.10.1038/clpt.2013.2Suche in Google Scholar PubMed PubMed Central

[123] Nevels RM, Gontkovsky ST, Williams BE. Paroxetine – the antidepressant from hell? Probably not, but caution required. Psychopharmacol Bull. 2016;46:77–104.10.64719/pb.4345Suche in Google Scholar

[124] Alvares GA, Quintana DS, Hickie IB, Guastella AJ. Autonomic nervous system dysfunction in psychiatric disorders and the impact of psychotropic medications: a systematic review and meta-analysis. J Psychiatry Neurosci. 2016;41:89–104.10.1503/jpn.140217Suche in Google Scholar PubMed PubMed Central

[125] Diaper A, Rich AS, Wilson SJ, Craig K, Dourish CT, Dawson GR, et al. Changes in cardiovascular function after venlafaxine but not pregabalin in healthy volunteers: a double-blind, placebo-controlled study of orthostatic challenge, blood pressure and heart rate. Hum Psychopharmacol. 2013;28:562–75.10.1002/hup.2346Suche in Google Scholar PubMed

[126] Vuppalanchi R, Hayashi PH, Chalasani N, Fontana RJ, Bonkovsky H, Saxena R, et al. Duloxetine hepatotoxicity: a case-series from the drug-induced liver injury network. Aliment Pharmacol Ther. 2010;32:1174–83.10.1111/j.1365-2036.2010.04449.xSuche in Google Scholar PubMed PubMed Central

[127] Lee WM. Drug-induced hepatotoxicity. N Engl J Med. 2003;349:474–85.10.1056/NEJMra021844Suche in Google Scholar PubMed

[128] Taylor D, Lenox-Smith A, Bradley A. A review of the suitability of duloxetine and venlafaxine for use in patients with depression in primary care with a focus on cardiovascular safety, suicide and mortality due to antidepressant overdose. Ther Adv Psychopharmacol. 2013;3:151–61.10.1177/2045125312472890Suche in Google Scholar PubMed PubMed Central

[129] Mease PJ, Zimetbaum PJ, Duh MS, Vekeman F, Guerin A, Boerstoel-Streefland M, et al. Epidemiologic evaluation of cardiovascular risk in patients receiving milnacipran, venlafaxine, or amitriptyline: evidence from French health data. Ann Pharmacother. 2011;45:179–188.10.1345/aph.1P391Suche in Google Scholar PubMed

[130] Deardorff WJ, Grossberg GT. The pharmacology and clinical use of the antidepressants vilazodone, levomilnacipran, and vortioxetine for depression in the elderly. Curr Geriatr Rep. 2015;4:301–11.10.1007/s13670-015-0140-ySuche in Google Scholar

[131] Asnis GM, Henderson MA. Levomilnacipran for the treatment of major depressive disorder: a review. Neuropsychiatr Dis Treat. 2015;11:125–35.10.2147/NDT.S54710Suche in Google Scholar PubMed PubMed Central

[132] Mago R, Forero G, Greenberg WM, Gommoll C, Chen C. Safety and tolerability of levomilnacipran ER in major depressive disorder: results from an open-label, 48-week extension study. Clin Drug Investig. 2013;33:761–71.10.1007/s40261-013-0126-5Suche in Google Scholar PubMed PubMed Central

[133] Roman MW, Wilkinson SM. Vortioxetine (Brintellix(R)) and levomilnacipran (Fetzima(R)): the two newest additions to the antidepressant formulary. Issues Ment Health Nurs. 2014;35:972–4.10.3109/01612840.2014.955155Suche in Google Scholar PubMed

[134] Annapandian VM, John GT, Mathew BS, Fleming DH. Pharmacokinetic interaction between sodium valproate and mycophenolate in renal allograft recipients. Transplantation. 2009;88:1143–5.10.1097/TP.0b013e3181bb99ffSuche in Google Scholar PubMed

[135] Ho JM, Gomes T, Straus SE, Austin PC, Mamdani M, Juurlink DN. Adverse cardiac events in older patients receiving venlafaxine: a population-based study. J Clin Psychiatry. 2014;75:e552–8.10.4088/JCP.13m08508Suche in Google Scholar PubMed

[136] Lee YC, Lin CH, Lin MS, Lin JW, Chang CH, Lai MS. Effects of selective serotonin reuptake inhibitors versus tricyclic antidepressants on cerebrovascular events: a nationwide population-based cohort study. J Clin Psychopharmacol. 2013;33:782–9.10.1097/JCP.0b013e31829c970eSuche in Google Scholar PubMed

[137] Olesen OV, Linnet K. Metabolism of the tricyclic antidepressant amitriptyline by cDNA-expressed human cytochrome P450 enzymes. Pharmacology. 1997;55:235–43.10.1159/000139533Suche in Google Scholar PubMed

[138] Kiyan S, Aksay E, Yanturali S, Atilla R, Ersel M. Acute myocardial infarction associated with amitriptyline overdose. Basic Clin Pharmacol Toxicol. 2006;98:462–6.10.1111/j.1742-7843.2006.pto_387.xSuche in Google Scholar PubMed

[139] Waslick B. Cardiac effects of desipramine. J Am Acad Child Adolesc Psychiatry. 1995;34:125–6.10.1097/00004583-199502000-00001Suche in Google Scholar PubMed

[140] Waslick BD, Walsh BT, Greenhill LL, Giardina EG, Sloan RP, Bigger JT, et al. Cardiovascular effects of desipramine in children and adults during exercise testing. J Am Acad Child Adolesc Psychiatry. 1999;38:179–86.10.1097/00004583-199902000-00017Suche in Google Scholar PubMed

[141] Biederman J, Thisted RA, Greenhill LL, Ryan ND. Estimation of the association between desipramine and the risk for sudden death in 5- to 14-year-old children. J Clin Psychiatry. 1995;56:87–93.Suche in Google Scholar

[142] Raskind M, Veith R, Barnes R, Gumbrecht G. Cardiovascular and antidepressant effects of imipramine in the treatment of secondary depression in patients with ischemic heart disease. Am J Psychiatry. 1982;139:1114–7.10.1097/00004714-198304000-00021Suche in Google Scholar

[143] Roose SP, Glassman AH, Giardina EG, Johnson LL, Walsh BT, Bigger JT, Jr. Cardiovascular effects of imipramine and bupropion in depressed patients with congestive heart failure. J Clin Psychopharmacol. 1987;7:247–51.10.1097/00004714-198708000-00007Suche in Google Scholar

[144] Tulen JH, Bruijn JA, de Man KJ, Pepplinkhuizen L, van den Meiracker AH, Man in ’t Veld AJ. Cardiovascular variability in major depressive disorder and effects of imipramine or mirtazapine (Org 3770). J Clin Psychopharmacol. 1996;16:135–45.10.1097/00004714-199604000-00006Suche in Google Scholar PubMed

[145] Yeragani VK, Pesce V, Jayaraman A, Roose S. Major depression with ischemic heart disease: effects of paroxetine and nortriptyline on long-term heart rate variability measures. Biol Psychiatry. 2002;52:418–29.10.1016/S0006-3223(02)01394-XSuche in Google Scholar

[146] Mago R, Tripathi N, Andrade C. Cardiovascular adverse effects of newer antidepressants. Expert Rev Neurother. 2014;14:539–51.10.1586/14737175.2014.908709Suche in Google Scholar PubMed

[147] Yeh TC, Kao LC, Tzeng NS, Kuo TB, Huang SY, Chang CC, et al. Heart rate variability in major depressive disorder and after antidepressant treatment with agomelatine and paroxetine: findings from the Taiwan Study of Depression and Anxiety (TAISDA). Prog Neuropsychopharmacol Biol Psychiatry. 2016;64:60–7.10.1016/j.pnpbp.2015.07.007Suche in Google Scholar PubMed

[148] Terhardt J, Lederbogen F, Feuerhack A, Hamann-Weber B, Gilles M, Schilling C, et al. Heart rate variability during antidepressant treatment with venlafaxine and mirtazapine. Clin Neuropharmacol. 2013;36:198–202.10.1097/WNF.0b013e3182a76fbbSuche in Google Scholar PubMed

[149] van Melle JP, de Jonge P, Honig A, Schene AH, Kuyper AM, Crijns HJ, et al. Effects of antidepressant treatment following myocardial infarction. Br J Psychiatry. 2007;190:460–6.10.1192/bjp.bp.106.028647Suche in Google Scholar PubMed

[150] de Jonge P, Honig A, van Melle JP, Schene AH, Kuyper AM, Tulner D, et al. Nonresponse to treatment for depression following myocardial infarction: association with subsequent cardiac events. Am J Psychiatry. 2007;164:1371–8.10.1176/appi.ajp.2007.06091492Suche in Google Scholar PubMed

[151] Lee S, Lee HA, Kim SJ, Kim KS. Cellular mechanisms for trazodone-induced cardiotoxicity. Hum Exp Toxicol. 2016;35:501–10.10.1177/0960327115595683Suche in Google Scholar PubMed

[152] Orsolini L, Tomasetti C, Valchera A, Iasevoli F, Buonaguro EF, Fornaro M, et al. Current and future perspectives on the major depressive disorder: focus on the new multimodal antidepressant vortioxetine. CNS Neurol Disord Drug Targets. 2017;16:65–92.10.2174/1871527315666161025140111Suche in Google Scholar PubMed

[153] Salagre E, Sole B, Tomioka Y, Fernandes BS, Hidalgo-Mazzei D, Garriga M, et al. Treatment of neurocognitive symptoms in unipolar depression: a systematic review and future perspectives. J Affect Disord. 2017;221:205–21.10.1016/j.jad.2017.06.034Suche in Google Scholar PubMed

[154] Talmon M, Rossi S, Pastore A, Cattaneo CI, Brunelleschi S, Fresu LG. Vortioxetine exerts anti-inflammatory and immunomodulatory effects on human monocytes/macrophages. Br J Pharmacol. 2018;175:113–24.10.1111/bph.14074Suche in Google Scholar PubMed PubMed Central

[155] Wagner G, Schultes MT, Titscher V, Teufer B, Klerings I, Gartlehner G. Efficacy and safety of levomilnacipran, vilazodone and vortioxetine compared with other second-generation antidepressants for major depressive disorder in adults: a systematic review and network meta-analysis. J Affect Disord. 2018;228:1–12.10.1016/j.jad.2017.11.056Suche in Google Scholar

[156] Cohen HW, Gibson G, Alderman MH. Excess risk of myocardial infarction in patients treated with antidepressant medications: association with use of tricyclic agents. Am J Med. 2000;108:2–8.10.1016/S0002-9343(99)00301-0Suche in Google Scholar

[157] Yekehtaz H, Farokhnia M, Akhondzadeh S. Cardiovascular considerations in antidepressant therapy: an evidence-based review. J Tehran Heart Cent. 2013;8:169–76.Suche in Google Scholar

[158] Katsi VK, Marketou M, Vamvakou G, Makris T, Tousoulis D, Stefanadis CI, et al. Novel antidepressant drugs, arterial hypertension and cardiovascular disease. Recent Pat Cardiovasc Drug Discov. 2013;8:178–85.10.2174/1574890109666140407154738Suche in Google Scholar PubMed

[159] Ventriglio A, Gentile A, Stella E, Bellomo A. Metabolic issues in patients affected by schizophrenia: clinical characteristics and medical management. Front Neurosci. 2015;9:297.10.3389/fnins.2015.00297Suche in Google Scholar PubMed PubMed Central

[160] (PhVWP) EPWP. Public assessment report on antipsychotics and cerebrovascular accident. London: Medicines and Healthcare Products Regulatory Agency; 2006.Suche in Google Scholar

[161] FDA. FDA requests boxed warnings on older class of antipsychotic drugs news release. Silver Spring: US Food and Drug Administration; 2008.Suche in Google Scholar

[162] Douglas IJ, Smeeth L. Exposure to antipsychotics and risk of stroke: self controlled case series study. BMJ. 2008;337:a1227.10.1136/bmj.a1227Suche in Google Scholar PubMed PubMed Central

[163] Barnett MJ, Wehring H, Perry PJ. Comparison of risk of cerebrovascular events in an elderly VA population with dementia between antipsychotic and nonantipsychotic users. J Clin Psychopharmacol. 2007;27:595–601.10.1097/jcp.0b013e31815a2531Suche in Google Scholar PubMed

[164] Finkel S, Kozma C, Long S, Greenspan A, Mahmoud R, Baser O, et al. Risperidone treatment in elderly patients with dementia: relative risk of cerebrovascular events versus other antipsychotics. Int Psychogeriatr. 2005;17:617–29.10.1017/S1041610205002280Suche in Google Scholar PubMed

[165] Gill SS, Rochon PA, Herrmann N, Lee PE, Sykora K, Gunraj N, et al. Atypical antipsychotic drugs and risk of ischaemic stroke: population based retrospective cohort study. BMJ. 2005;330:445.10.1136/bmj.38330.470486.8FSuche in Google Scholar PubMed PubMed Central

[166] Shin JY, Choi NK, Lee J, Seong JM, Park MJ, Lee SH, et al. Risk of ischemic stroke associated with the use of antipsychotic drugs in elderly patients: a retrospective cohort study in Korea. PLoS One. 2015;10:e0119931.10.1371/journal.pone.0119931Suche in Google Scholar PubMed PubMed Central

[167] Vasilyeva I, Biscontri RG, Enns MW, Metge CJ, Alessi-Severini S. Adverse events in elderly users of antipsychotic pharmacotherapy in the province of Manitoba: a retrospective cohort study. J Clin Psychopharmacol. 2013;33:24–30.10.1097/JCP.0b013e31827934a4Suche in Google Scholar PubMed

[168] Rao A, Suliman A, Story G, Vuik S, Aylin P, Darzi A. Meta-analysis of population-based studies comparing risk of cerebrovascular accident associated with first- and second-generation antipsychotic prescribing in dementia. Int J Methods Psychiatr Res. 2016;25:289–98.10.1002/mpr.1509Suche in Google Scholar PubMed PubMed Central

[169] Farlow MR, Shamliyan TA. Benefits and harms of atypical antipsychotics for agitation in adults with dementia. Eur Neuropsychopharmacol. 2017;27:217–31.10.1016/j.euroneuro.2017.01.002Suche in Google Scholar PubMed

[170] Kano M, Toyoshi T, Iwasaki S, Kato M, Shimizu M, Ota T. QT PRODACT: usability of miniature pigs in safety pharmacology studies: assessment for drug-induced QT interval prolongation. J Pharmacol Sci. 2005;99:501–11.10.1254/jphs.QT-C13Suche in Google Scholar

[171] Acciavatti T, Martinotti G, Corbo M, Cinosi E, Lupi M, Ricci F, et al. Psychotropic drugs and ventricular repolarisation: The effects on QT interval, T-peak to T-end interval and QT dispersion. J Psychopharmacol. 2017;31:453–460.10.1177/0269881116684337Suche in Google Scholar PubMed

[172] Polcwiartek C, Kragholm K, Schjerning O, Graff C, Nielsen J. Cardiovascular safety of antipsychotics: a clinical overview. Expert Opin Drug Saf. 2016;15:679–88.10.1517/14740338.2016.1161021Suche in Google Scholar PubMed

[173] Carra G, Crocamo C, Bartoli F, Lax A, Tremolada M, Lucii C, et al. First-generation antipsychotics and QTc: any role for mediating variables? Hum Psychopharmacol. 2016;31:313–8.10.1002/hup.2540Suche in Google Scholar PubMed

[174] Barbui C, Bighelli I, Carra G, Castellazzi M, Lucii C, Martinotti G, et al. Antipsychotic dose mediates the association between polypharmacy and corrected QT interval. PLoS One. 2016;11:e0148212.10.1371/journal.pone.0148212Suche in Google Scholar PubMed PubMed Central

[175] Wu CS, Tsai YT, Tsai HJ. Antipsychotic drugs and the risk of ventricular arrhythmia and/or sudden cardiac death: a nation-wide case-crossover study. J Am Heart Assoc. 2015;4. DOI: 10.1161/JAHA.114.001568.Suche in Google Scholar PubMed PubMed Central

[176] Takeuchi H, Suzuki T, Remington G, Uchida H. Antipsychotic polypharmacy and corrected QT interval: a systematic review. Can J Psychiatry. 2015;60:215–22.10.1177/070674371506000503Suche in Google Scholar PubMed PubMed Central

[177] Chohan PS, Mittal R, Javed A. Antipsychotic medication and QT prolongation. Pak J Med Sci. 2015;31:1269–71.10.12669/pjms.315.8998Suche in Google Scholar

[178] Shah AA, Aftab A, Coverdale J. QTc prolongation with antipsychotics: is routine ECG monitoring recommended? J Psychiatr Pract. 2014;20:196–206.10.1097/01.pra.0000450319.21859.6dSuche in Google Scholar PubMed

[179] Fusar-Poli P, Kempton MJ, Rosenheck RA. Efficacy and safety of second-generation long-acting injections in schizophrenia: a meta-analysis of randomized-controlled trials. Int Clin Psychopharmacol. 2013;28:57–66.10.1097/YIC.0b013e32835b091fSuche in Google Scholar

[180] DeDea L. QT prolongation: a critical adverse effect of some medications. JAAPA. 2013;26:11.10.1097/01720610-201302000-00002Suche in Google Scholar

[181] De Hert M, Detraux J, van Winkel R, Yu W, Correll CU. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol. 2011;8:114–26.10.1038/nrendo.2011.156Suche in Google Scholar

[182] van Noord C, Straus SM, Sturkenboom MC, Hofman A, Aarnoudse AJ, Bagnardi V, et al. Psychotropic drugs associated with corrected QT interval prolongation. J Clin Psychopharmacol. 2009;29:9–15.10.1097/JCP.0b013e318191c6a8Suche in Google Scholar

[183] Ray WA, Chung CP, Murray KT, Hall K, Stein CM. Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med. 2009;360:225–35.10.1056/NEJMoa0806994Suche in Google Scholar

[184] Haddad PM, Anderson IM. Antipsychotic-related QTc prolongation, torsade de pointes and sudden death. Drugs. 2002;62:1649–71.10.2165/00003495-200262110-00006Suche in Google Scholar

[185] Knudson JF, Kortepeter C, Dubitsky GM, Ahmad SR, Chen M. Antipsychotic drugs and venous thromboembolism. Lancet. 2000;356:252–3.10.1016/S0140-6736(05)74504-9Suche in Google Scholar

[186] Hagg S, Tatting P, Spigset O. Olanzapine and venous thromboembolism. Int Clin Psychopharmacol. 2003;18:299–300.10.1097/01.yic.0000085241.99018.30Suche in Google Scholar

[187] Hardwick JC, Ferguson EJ. Antipsychotic drugs and venous thromboembolism. Lancet. 2001;357:391; author reply 391–2.10.1016/S0140-6736(05)71522-1Suche in Google Scholar

[188] Maly R, Masopust J, Hosak L, Konupcikova K. Assessment of risk of venous thromboembolism and its possible prevention in psychiatric patients. Psychiatry Clin Neurosci. 2008;62:3–8.10.1111/j.1440-1819.2007.01773.xSuche in Google Scholar PubMed

[189] Matsumoto M, Konno T, Tamba K, Abe T, Kato S, Kajii E. Two cases of deep vein thrombosis associated with antipsychotic drug use. Psychiatry Clin Neurosci. 2004;58:450–1.10.1111/j.1440-1819.2004.01284.xSuche in Google Scholar

[190] Numata S, Kato O, Misawa H, Tokuda H, Kasahara T, Ohmori T. Left atrial thrombosis associated with antipsychotic drugs. Prog Neuropsychopharmacol Biol Psychiatry. 2005;29:153–5.10.1016/j.pnpbp.2004.08.010Suche in Google Scholar

[191] Pantel J, Schroder J, Eysenbach K, Mundt C. Two cases of deep vein thrombosis associated with a combined paroxetine and zotepine therapy. Pharmacopsychiatry. 1997;30:109–111.10.1055/s-2007-979493Suche in Google Scholar

[192] Parker C, Coupland C, Hippisley-Cox J. Antipsychotic drugs and risk of venous thromboembolism: nested case-control study. BMJ. 2010;341:c4245.10.1136/bmj.c4245Suche in Google Scholar

[193] Ray JG, Mamdani MM, Yeo EL. Antipsychotic and antidepressant drug use in the elderly and the risk of venous thromboembolism. Thromb Haemost. 2002;88:205–9.10.1055/s-0037-1613188Suche in Google Scholar

[194] Shulman M, Jennifer Njoku I, Manu P. Thrombotic complications of treatment with antipsychotic drugs. Minerva Med. 2013;104:175–84.Suche in Google Scholar

[195] Stansby G, Noble S, Howes O. The importance of venous thromboembolism – a physical consequence of psychiatric treatments. Int J Clin Pract. 2010;64:1005–6.10.1111/j.1742-1241.2010.02435.xSuche in Google Scholar

[196] Thomassen R, Vandenbroucke JP, Rosendaal FR. Antipsychotic medication and venous thrombosis. Br J Psychiatry. 2001;179:63–6.10.1192/bjp.179.1.63Suche in Google Scholar

[197] Werring D, Hacking D, Losseff N, Jager HR, Walsh M, Foong J. Cerebral venous sinus thrombosis may be associated with clozapine. J Neuropsychiatry Clin Neurosci. 2009;21:343–5.10.1176/jnp.2009.21.3.343aSuche in Google Scholar

[198] Zornberg GL, Jick H. Antipsychotic drug use and risk of first-time idiopathic venous thromboembolism: a case-control study. Lancet. 2000;356:1219–23.10.1016/S0140-6736(00)02784-7Suche in Google Scholar

[199] Liperoti R, Pedone C, Lapane KL, Mor V, Bernabei R, Gambassi G. Venous thromboembolism among elderly patients treated with atypical and conventional antipsychotic agents. Arch Intern Med. 2005;165:2677–82.10.1001/archinte.165.22.2677Suche in Google Scholar PubMed

[200] Hagg S, Spigset O. Antipsychotic-induced venous thromboembolism: a review of the evidence. CNS Drugs. 2002;16:765–76.10.2165/00023210-200216110-00005Suche in Google Scholar

[201] Smith M, Hopkins D, Peveler RC, Holt RI, Woodward M, Ismail K. First- v. second-generation antipsychotics and risk for diabetes in schizophrenia: systematic review and meta-analysis. Br J Psychiatry. 2008;192:406–11.10.1192/bjp.bp.107.037184Suche in Google Scholar

[202] Hartling L, Abou-Setta AM, Dursun S, Mousavi SS, Pasichnyk D, Newton AS. Antipsychotics in adults with schizophrenia: comparative effectiveness of first-generation versus second-generation medications: a systematic review and meta-analysis. Ann Intern Med. 2012;157:498–511.10.7326/0003-4819-157-7-201210020-00525Suche in Google Scholar

[203] Lewington S, Clarke R, Qizilbash N, Peto R, Collins R, Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360:1903–13.10.1016/S0140-6736(02)11911-8Suche in Google Scholar

[204] Mitchell AJ, Vancampfort D, Sweers K, van Winkel R, Yu W, De Hert M. Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders – a systematic review and meta-analysis. Schizophr Bull. 2013;39:306–18.10.1093/schbul/sbr148Suche in Google Scholar

[205] Gugger JJ. Antipsychotic pharmacotherapy and orthostatic hypotension: identification and management. CNS Drugs. 2011;25:659–71.10.2165/11591710-000000000-00000Suche in Google Scholar

[206] Kahl KG, Westhoff-Bleck M, Kruger THC. Effects of psychopharmacological treatment with antipsychotic drugs on the vascular system. Vascul Pharmacol. 2018;100:20–5.10.1016/j.vph.2017.09.001Suche in Google Scholar

[207] Abhijnhan A, Adams CE, David A, Ozbilen M. Depot fluspirilene for schizophrenia. Cochrane Database Syst Rev. 2007;CD001718.10.1002/14651858.CD001718.pub2Suche in Google Scholar

[208] Su KP, Shen WW, Chuang CL, Chen KP, Chen CC. A pilot cross-over design study on QTc interval prolongation associated with sulpiride and haloperidol. Schizophr Res. 2003;59:93–4.10.1016/S0920-9964(01)00336-XSuche in Google Scholar

[209] Meyer-Massetti C, Cheng CM, Sharpe BA, Meier CR, Guglielmo BJ. The FDA extended warning for intravenous haloperidol and torsades de pointes: how should institutions respond? J Hosp Med. 2010;5:E8–16.10.1002/jhm.691Suche in Google Scholar PubMed

[210] Haverkamp W, Deuschle M. [Lengthening of QT interval by antipsychotic drugs]. Nervenarzt. 2006;77:276, 278–80, 282–4 passim.10.1007/s00115-005-1966-xSuche in Google Scholar PubMed

[211] Andole SN. An unusual presentation of cortical venous thrombosis and its association with typical antipsychotics. BMJ Case Rep. 2011. DOI: 10.1136/bcr.07.2011.4542.Suche in Google Scholar PubMed PubMed Central

[212] Lacey M, Jayaram MB. Zuclopenthixol versus placebo for schizophrenia. Cochrane Database Syst Rev. 2015;CD010598.10.1002/14651858.CD010598Suche in Google Scholar

[213] Mauri MC, Paletta S, Maffini M, Colasanti A, Dragogna F, Di Pace C, et al. Clinical pharmacology of atypical antipsychotics: an update. EXCLI J. 2014;13:1163–91.Suche in Google Scholar

[214] Jin H, Shih PA, Golshan S, Mudaliar S, Henry R, Glorioso DK, et al. Comparison of longer-term safety and effectiveness of 4 atypical antipsychotics in patients over age 40: a trial using equipoise-stratified randomization. J Clin Psychiatry. 2013;74:10–8.10.4088/JCP.12m08001Suche in Google Scholar PubMed PubMed Central

[215] Isbister GK, Balit CR, Macleod D, Duffull SB. Amisulpride overdose is frequently associated with QT prolongation and torsades de pointes. J Clin Psychopharmacol. 2010;30:391–5.10.1097/JCP.0b013e3181e5c14cSuche in Google Scholar PubMed

[216] Isbister GK, Murray L, John S, Hackett LP, Haider T, O’Mullane P, et al. Amisulpride deliberate self-poisoning causing severe cardiac toxicity including QT prolongation and torsades de pointes. Med J Aust. 2006;184:354–6.10.5694/j.1326-5377.2006.tb00272.xSuche in Google Scholar PubMed

[217] Lynch MJ, Woods J, George N, Gerostamoulos D. Fatality due to amisulpride toxicity: a case report. Med Sci Law. 2008;48:173–7.10.1258/rsmmsl.48.2.173Suche in Google Scholar PubMed

[218] Tracqui A, Mutter-Schmidt C, Kintz P, Berton C, Mangin P. Amisulpride poisoning: a report on two cases. Hum Exp Toxicol. 1995;14:294–8.10.1177/096032719501400310Suche in Google Scholar PubMed

[219] Ward DI. Two cases of amisulpride overdose: a cause for prolonged QT syndrome. Emerg Med Australas. 2005;17:274–6.10.1111/j.1742-6723.2005.00734.xSuche in Google Scholar PubMed

[220] Mallikaarjun S, Shoaf SE, Boulton DW, Bramer SL. Effects of hepatic or renal impairment on the pharmacokinetics of aripiprazole. Clin Pharmacokinet. 2008;47:533–42.10.2165/00003088-200847080-00003Suche in Google Scholar PubMed

[221] Polcwiartek C, Sneider B, Graff C, Taylor D, Meyer J, Kanters JK, et al. The cardiac safety of aripiprazole treatment in patients at high risk for torsade: a systematic review with a meta-analytic approach. Psychopharmacology (Berl). 2015;232:3297–308.10.1007/s00213-015-4024-9Suche in Google Scholar PubMed

[222] Lim AM, Dhillon R, Tibrewal P, Bastiampillai T, Nguyen BD. Clozapine, immunosuppressants and renal transplantation. Asian J Psychiatry. 2017;23:118.10.1016/j.ajp.2016.07.018Suche in Google Scholar PubMed

[223] Hollingworth SA, Winckel K, Saiepour N, Wheeler AJ, Myles N, Siskind D. Clozapine-related neutropenia, myocarditis and cardiomyopathy adverse event reports in Australia 1993–2014. Psychopharmacology (Berl). 2018;235:1915–21.10.1007/s00213-018-4881-0Suche in Google Scholar PubMed

[224] Stollberger C, Huber JO, Finsterer J. Antipsychotic drugs and QT prolongation. Int Clin Psychopharmacol. 2005;20:243–51.10.1097/01.yic.0000166405.49473.70Suche in Google Scholar PubMed

[225] Citrome L. Lurasidone for schizophrenia: a brief review of a new second-generation antipsychotic. Clin Schizophr Relat Psychoses. 2011;4:251–7.10.3371/CSRP.4.4.5Suche in Google Scholar PubMed

[226] Greenberg WM, Citrome L. Pharmacokinetics and pharmacodynamics of lurasidone hydrochloride, a second-generation antipsychotic: a systematic review of the published literature. Clin Pharmacokinet. 2017;56:493–503.10.1007/s40262-016-0465-5Suche in Google Scholar PubMed

[227] Callaghan JT, Bergstrom RF, Ptak LR, Beasley CM. Olanzapine. Pharmacokinetic and pharmacodynamic profile. Clin Pharmacokinet. 1999;37:177–93.10.2165/00003088-199937030-00001Suche in Google Scholar PubMed

[228] Samtani MN, Vermeulen A, Stuyckens K. Population pharmacokinetics of intramuscular paliperidone palmitate in patients with schizophrenia: a novel once-monthly, long-acting formulation of an atypical antipsychotic. Clin Pharmacokinet. 2009;48:585–600.10.2165/11316870-000000000-00000Suche in Google Scholar PubMed

[229] Mauri MC, Volonteri LS, Colasanti A, Fiorentini A, De Gaspari IF, Bareggi SR. Clinical pharmacokinetics of atypical antipsychotics: a critical review of the relationship between plasma concentrations and clinical response. Clin Pharmacokinet. 2007;46:359–88.10.2165/00003088-200746050-00001Suche in Google Scholar PubMed

[230] Mahatthanatrakul W, Sriwiriyajan S, Ridtitid W, Boonleang J, Wongnawa M, Rujimamahasan N, et al. Effect of cytochrome P450 3A4 inhibitor ketoconazole on risperidone pharmacokinetics in healthy volunteers. J Clin Pharm Ther. 2012;37:221–5.10.1111/j.1365-2710.2011.01271.xSuche in Google Scholar PubMed

[231] Gopal S, Hough D, Karcher K, Nuamah I, Palumbo J, Berlin JA, et al. Risk of cardiovascular morbidity with risperidone or paliperidone treatment: analysis of 64 randomized, double-blind trials. J Clin Psychopharmacol. 2013;33:157–61.10.1097/JCP.0b013e318283983fSuche in Google Scholar PubMed

[232] Katz I, de Deyn PP, Mintzer J, Greenspan A, Zhu Y, Brodaty H. The efficacy and safety of risperidone in the treatment of psychosis of Alzheimer’s disease and mixed dementia: a meta-analysis of 4 placebo-controlled clinical trials. Int J Geriatr Psychiatry. 2007;22:475–84.10.1002/gps.1792Suche in Google Scholar PubMed

[233] Camm AJ, Karayal ON, Meltzer H, Kolluri S, O’Gorman C, Miceli J, et al. Ziprasidone and the corrected QT interval: a comprehensive summary of clinical data. CNS Drugs. 2012;26:351–65.10.2165/11599010-000000000-00000Suche in Google Scholar PubMed